Alterome Therapeutics has developed ALTA-2618, a potent and selective covalent inhibitor targeting the AKT1 E17K mutation found in various cancers. This allosteric inhibitor has demonstrated strong anti-tumor activity in preclinical models expressing AKT1 E17K, offering a promising therapeutic approach for patients with limited treatment options.
AKT1 E17K is a clinically validated oncogene that plays a crucial role in driving the development and progression of cancers, including breast, endometrial, and prostate cancers. ALTA-2618 selectively binds to and inhibits AKT1 E17K, disrupting its oncogenic signaling and leading to cellular dysfunction and tumor regression.
In preclinical studies, ALTA-2618 exhibited potent anti-tumor activity against PDX models expressing AKT1 E17K, resulting in significant tumor regression. Furthermore, the compound demonstrated favorable pharmacokinetic properties, including oral bioavailability and sustained target engagement, supporting its potential for clinical development.
Based on these promising preclinical findings, Alterome Therapeutics plans to initiate first-in-human clinical trials for ALTA-2618 in 2024. This study will evaluate the safety, tolerability, and efficacy of ALTA-2618 in patients with AKT1 E17K-driven cancers who have exhausted current treatment options.
The development of ALTA-2618 represents a significant milestone in Alterome Therapeutics’ mission to discover精准 therapies that selectively target cancer-specific mutations. This approach aims to improve patient outcomes by maximizing therapeutic efficacy while minimizing adverse effects. The upcoming clinical trials of ALTA-2618 will provide valuable insights into the potential of this novel inhibitor to address a significant unmet medical need in AKT1 E17K-driven cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
